Aridis Pharmaceuticals, Inc. (ARDS)
ARDS Stock Price Chart
Explore Aridis Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ARDS price movements and trends.
ARDS Company Profile
Discover essential business fundamentals and corporate details for Aridis Pharmaceuticals, Inc. (ARDS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Aug 2018
Employees
37.00
Website
https://www.aridispharma.comCEO
Vu L. Truong
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
ARDS Financial Timeline
Browse a chronological timeline of Aridis Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 4 Jun 2025
Earnings released on 29 May 2025
Earnings released on 28 Mar 2025
Earnings released on 18 Nov 2024
Earnings released on 27 Sept 2024
Earnings released on 27 Jun 2024
Earnings released on 1 Jan 2024
Earnings released on 6 Nov 2023
EPS came in at -$0.02 surpassing the estimated -$0.10 by +80.00%, while revenue for the quarter reached $417.00K , beating expectations by +39.00%.
Earnings released on 13 Sept 2023
EPS came in at $0.33 , while revenue for the quarter reached $19.65M .
Earnings released on 22 May 2023
EPS came in at -$0.27 .
Earnings released on 29 Mar 2023
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.59%.
Earnings released on 21 Nov 2022
EPS came in at -$0.42 falling short of the estimated -$0.15 by -176.46%.
Earnings released on 16 Aug 2022
EPS came in at -$0.45 falling short of the estimated -$0.06 by -650.00%, while revenue for the quarter reached $292.00K .
Earnings released on 16 May 2022
EPS came in at -$0.44 surpassing the estimated -$0.51 by +13.73%.
Earnings released on 31 Mar 2022
EPS came in at -$0.92 falling short of the estimated -$0.58 by -58.62%, while revenue for the quarter reached $570.00K .
Earnings released on 10 Nov 2021
EPS came in at -$1.94 falling short of the estimated -$0.54 by -259.26%, while revenue for the quarter reached $98.00K , missing expectations by -86.72%.
Earnings released on 12 Aug 2021
EPS came in at -$0.55 surpassing the estimated -$0.57 by +3.51%, while revenue for the quarter reached $33.00K , meeting expectations.
Earnings released on 11 May 2021
EPS came in at -$0.77 falling short of the estimated -$0.60 by -28.33%.
Earnings released on 30 Mar 2021
EPS came in at -$0.59 falling short of the estimated -$0.54 by -9.26%.
Earnings released on 20 Nov 2020
EPS came in at -$0.65 falling short of the estimated -$0.55 by -18.18%.
ARDS Stock Performance
Access detailed ARDS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.